What type of drug is Emgality?
Medically reviewed by Judith Stewart, BPharm. Last updated on Feb 11, 2021.
Emgality (galcanezumab-gnlm) is a calcitonin gene-related peptide (CGRP) antagonist monoclonal antibody used for the prevention of migraine, and for the treatment of eposidic cluster headache in adults.
There are four approved calcitonin gene-related peptide (CGRP) antagonists that are monoclonal antibodies:
- Aimovig (erenumab-aooe)
- Ajovy (fremanezumab-vfrm)
- Emgality (galcanezumab-gnlm)
- Vyepti (eptinezumab-jjmr)
All four drugs are indicated for the preventative treatment of migraine. Emgality is the only CGRP antagonist that is also approved for the treatment of episodic cluster headache.
How do calcitonin gene-related peptide (CGRP) antagonists work?
When CGRP binds to its receptor, a cascade of events such as vasodilation and protein leakage begin that results in inflammation and pain associated with migraine.
- Emgality, Ajovy and Vyepti work by binding to the CGRP ligand and block its binding to the receptor to help prevent migraine pain.
- Aimovig selectively binds to the CGRP receptor (not the ligand) to block CGRP activation, thereby preventing migraine pain.
Related Medical Questions
- Does Emgality cause weight gain?
- How long does it take for Emgality to work?
- Do Emgality injections hurt?
- How does Emgality work?
- Emgality vs Aimovig - how do they compare?
- What are the new drugs for the treatment and prevention of migraine?
- Ubrelvy vs Emgality: How do they compare for migraines?
- What is the cost of the migraine drug Ajovy?
- What type of drug is Ajovy?